Last updated: February 20, 2026
What is NDC 72974-0415?
NDC 72974-0415 corresponds to Tucatinib, an oral tyrosine kinase inhibitor developed by Seattle Genetics. Approved by the FDA in April 2020 for adults with HER2-positive metastatic breast cancer, the drug is marketed under the brand name Tukysa.
Current Market Landscape
Approval and Indications
Tucatinib received accelerated approval based on response rates in clinical trials for patients with HER2-positive metastatic or locally advanced unresectable breast cancer who have received prior trastuzumab, pertuzumab, and chemotherapy.
Market Size and Key Players
- Primary indication: HER2-positive breast cancer.
- Incidence: Approx. 15-20% of breast cancers in the U.S.
- Market penetration: Limited initially, with accelerated adoption among oncologists.
- Competitors: Lapatinib, Neratinib, Tucatinib is positioned as an option especially for patients with brain metastases.
Commercial Launch and Uptake
- Initial sales (2020-2022): Estimated at $250M globally in 2022.
- Market growth factors:
- Expanding indications.
- Increased awareness.
- Broader insurance coverage.
- Strategic partnerships with payer networks.
Prescriber Dynamics
- Predominantly used by oncologists specializing in breast cancer.
- Growing adoption due to clinical advantage in CNS metastasis management.
Price Points and Revenue Generation
Current Wholesale Acquisition Cost (WAC)
- Listed at approximately $11,950 per month for a typical treatment course.
- Cost per year: Roughly $143,400 per patient.
Pricing Rationale
- The price aligns with other targeted oncology agents.
- Reflects innovation, manufacturing costs, and competitive landscape.
- Reimbursement largely through insurance, including Medicaid, Medicare, and commercial plans.
Impact on Revenue
| Year |
Estimated Sales |
Market Penetration |
Revenue Drivers |
| 2022 |
~$250M |
Moderate |
Expanded indications, approvals |
| 2023 |
~$350M |
Increased growth |
Greater prescriber acceptance |
| 2024 |
~$500M |
Stabilizing |
Potential new combinations, CNS use |
Price Projections and Market Trends
Short-Term (2023-2025)
- Price remains stable barring policy changes.
- Slight upward adjustment (~2-3%) expected annually, reflecting inflation and market competitiveness.
- Volume growth driven by expanded indications and increased prescriber familiarity.
Long-Term (2026-2030)
- Potential price reductions in response to biosimilar entry or generics if approved.
- Expected increases in sales volume, possibly reaching $800M-$1B annual sales globally.
- Price erosion likely if sustainable biosimilar products or similar drugs enter the market.
Factors Influencing Future Pricing
- FDA approvals for expanded indications, affecting volume and pricing.
- Competitive dynamics and biosimilar landscape.
- Changes in healthcare policies that influence drug pricing.
- Patient access programs and rebates.
Policy and Regulatory Environment
- Drug pricing negotiations under Medicare and Medicaid may impact net revenue.
- Possible inclusion in value-based reimbursement models.
- No current biosimilar approval; biosimilar development for Tucatinib unlikely in the near term.
Summary Table: Key Data Points
| Aspect |
Data Point |
| FDA Approval Date |
April 17, 2020 |
| Primary Indication |
HER2-positive metastatic breast cancer |
| Current Annual Revenue |
~$250M (2022 estimate) |
| WAC per Month |
~$11,950 |
| Launch Price |
Similar to other targeted agents (>$10,000/month) |
| Market Size (U.S.) |
15-20% of breast cancer cases (~3 million patients globally) |
| Expected Long-term Revenue |
Up to $1B globally (2026-2030) |
Key Takeaways
- Tucatinib is positioned in a niche but growing segment for HER2-positive breast cancer.
- Pricing remains high but stable, aligned with targeted therapies.
- Market growth driven by new indications, increased prescriber adoption, and global expansion.
- Competitive pressures and potential biosimilar developments could influence future pricing.
- Total revenue potential could approach $1B annually within five years.
FAQs
1. How does Tucatinib compare pricing-wise to similar drugs?
It is priced similarly to other targeted breast cancer therapies, around $11,950 per month, reflecting its novel mechanism and clinical benefits.
2. What factors could lead to significant price reductions?
The entry of biosimilars or generics, regulatory changes, or policy shifts targeting drug pricing could lead to reductions.
3. What is the future growth potential of Tucatinib?
Sales could reach $1B globally by 2026-2030, driven by expanding indications and increased global adoption.
4. How does the drug's indication affect its market size?
Its primary focus on HER2-positive breast cancer limits the global patient pool but captures a high-value segment of oncology drugs.
5. What are the main challenges in maintaining current pricing levels?
Market competition, policy reforms, and biosimilar entries could pressure pricing and margins.
References
[1] FDA. (2020). FDA approves tucatinib for breast cancer. Retrieved from https://www.fda.gov
[2] Seattle Genetics. (2022). Tucatinib (Tukysa) prescribing info. Retrieved from https://www.tukysa.com
[3] IQVIA. (2022). Oncology drug sales data.
[4] National Cancer Institute. (2022). Breast cancer statistics.
[5] Health Policy Reports. (2022). Oncology drug pricing trends.
Note: Market figures and price estimates are approximations based on publicly available data as of 2022-2023.
